2015 American Transplant Congress
Comparison of Efficacy and Renal Function in KidneyTransplant Recipients Receiving Tacrolimus (TAC)-Based Immunosuppressive Regimens in Combination With Everolimus (EVR) or Mycophenolate (MPA)
1Nephrology, Hospital do Rim UNIFESP, Sao Paulo, Brazil; 2Pathology, UNIFESP, Sao Paulo, Brazil.
Introduction: Acute rejection and renal function are associated with long-term renal allograft survival. We evaluated these outcomes in patients receiving reduced TAC exposure combined with…2015 American Transplant Congress
Treatment With Everolimus and Reduced-Exposure Cyclosporine Is Efficacious in De Novo Renal Transplant Recipients at Increased Risk for Efficacy Failure: Post-Hoc Analysis from the A2309 Study
1For the A2309 Study Group, Italy; 2Novartis, Basel, Switzerland.
Purpose: Data is limited on the effect of everolimus (EVR) based regimens in renal transplant recipients (RTxR) who are at increased risk for rejection and…2015 American Transplant Congress
Factors Affecting Efficacy Outcomes at 12 and 24-Months After Kidney Transplantation in Patients from the A2309 Study
1Novartis, Basel, Switzerland; 2A2309 Study Group, Basel, Switzerland; 3Novartis, East Hanover, NJ.
Purpose: Efficacy outcomes post-transplantation are influenced by donor and recipient variables and interactions between them. Here, we present data from a multivariate analysis of risk…2015 American Transplant Congress
Electronic Health Service to Improve Therapeutic Drug Monitoring of Immunosuppressants
PurposeTherapeutic drug monitoring (TDM) of immunosuppressants is critical to avoid rejection or toxic side effects by under- or over-immunosuppression after heart transplantation (HTx). Hence, in…
- « Previous Page
- 1
- …
- 10
- 11
- 12